333 Ravenswood Avenue
About SRI International
SRI International’s Biosciences Division carries out basic research, drug discovery and drug development, and provides contract services. SRI Biosciences has all of the resources necessary to take R&D from Idea to IND and Beyond™ —from initial discovery to human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI’s product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and other clients and partners advance well over 100 drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.
158 articles with SRI International
SRI International Awarded Contract Worth Up to $100M from National Institute of Allergy and Infectious Diseases for Radiation/Nuclear Medical Countermeasures
Grant extends SRI's long history of collaborations with the National Institutes of Health
Q BioMed Announces Strategic Partnership With SRI International for Formulation and Preclinical Development of QBM-001 for Pediatric Nonverbal Disorder in Autistic Children
Q Biomed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001, in support of Q BioMed's Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children.
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
Industry and technology analysis together with deep research capabilities offer clients enhanced market insights
SRI International announced a research agreement with Ionis Pharmaceuticals, combining SRI's proprietary FOX Three Molecular Guidance cellular targeting system (MGS) with Ionis' proprietary antisense drug-discovery platform.
Scientists From SRI International and Collaborations Pharma Identify Potential New Ebola Virus Therapy
The low molecular weight immunomodulatory drug has shown promising efficacy with 100 percent survival in an Ebola virus disease model.
SRI International Awarded $4.7 Million In Agreements To Manufacture And Test Vaccine Against Venezuelan Equine Encephalitis
SRI International Receives U.S. FDA Clearance For Investigational New Drug Application Evaluating Novel Oral Treatment To Combat Radiation Exposure
SRI International Receives $9 Million Contract To Support National Cancer Institute PREVENT Cancer Program
SRI International Biosciences Researchers Part Of Team Reporting New Cancer Therapy Strategy In Nature
SRI International Awarded $100 Million National Institute of Allergy And Infectious Diseases (NIAID) Contract To Develop Treatments For Radiation Exposure